Synthetic biology company, Intrexon Corporation, has acquired state-of-the-art laboratory operations in Budapest, Hungary from biocatalysts developer Codexis, Inc. The acquisition will expand Intrexon’s strain and protein development capabilities, as well as strengthen fermentation process optimization and scale-up. Intrexon’s Industrial Products Division (IPD) will absorb the Budapest laboratory staff.

Intrexon’s IPD is positioned to develop biologically based solutions across sectors – Health, Food, Energy, Environment, and Consumer – including bioproduction of APIs, for example novel anti-infectives, as well as engineering microbial biocatalysts for chemical and fuel production.